NAD+ 1g & Tirzepatide - A UK Report
The growing landscape of metabolic health in the UK is seeing significant interest in the pairing of high-dose NAD+ supplementation – often at 1g dosage – and the novel GLP-1 receptor agonist Retatrutide (or its related Tirzepatide). Clinicians are observing potential outcomes regarding metabolic